Antheia
PrivateLast Round
Series C
Extension
Jan 27, 2026
Total Funding Raised
$342M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Antheia is a biotechnology company that develops plant-inspired medicines using synthetic biology, informatics, and fermentation technology to create active pharmaceutical ingredients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Pharma Supply Chain, Drug Discovery, Clean Manufacturing
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antheia Comparables
Compare Antheia with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abiochem Biotechnology | 72% | |
| Vertexyn (Nanjing) Bioworks Co., Ltd. | 72% | |
| Fermelanta, Inc. | 71% |
Antheia Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jan 27, 2026 | ||||
| Series C | Jun 3, 2025 | ||||
| Grant | Dec 3, 2024 | ||||
| Grant | Jul 19, 2024 | ||||
| Series C | Jan 24, 2024 | ||||
Debt | Jun 22, 2022 |
Key People
Founding team and executive leadership
Antheia Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sherpalo Ventures | Series C Extension, Series C, Series B |
| America's Frontier Fund | Series C Extension |
| AFF | Series C Extension |
| Athos KG | Series C, Series C Extension |
| EDBI | Series C Extension, Series C |
| S-Cubed Capital | Series C Extension, Series C |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Recognized as a priority technology for public health and national security.
- Apr 23, 2026
Added Contract Pharma, a media/publishing SMB, as a customer.
Recent news
Latest coverage and updates
- receives_financingOct 30, 2026
On Oct 17th '26, Antheia receives a conditional $80B loan from the Department of Defense.
- partners_withOct 21, 2026
In 2024, Antheia partners with Phlow Corporation to support U.S. production of key starting materials for APIs by combining biomanufacturing and flow chemistry processes.
- expands_facilitiesOct 19, 2026
A proposed loan would support Antheia's commercial expansion and efforts to establish additional pharmaceutical ingredient production capacity in United States; the company discloses no specific manufacturing location, capacity, or completion timetable.
- recognized_asOct 18, 2026
Antheia's biosynthesis platform and domestic manufacturing capabilities are repeatedly recognized as priority technologies for building more resilient public health systems.
- is_developingOct 18, 2026
Antheia, a California-based pharmaceutical ingredient manufacturer, is developing oripavine using biosynthesis technology.
Antheia Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Antheia's valuation, stock price, and market status.
Is Antheia a public or private company?
Antheia is a private company.
What is the current stock price of Antheia?
Antheia is a private company, so its shares have no public market price. Caplight tracks Antheia's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Antheia worth (valuation)?
Valuation information for Antheia is not publicly available.
Can I buy Antheia stock?
Antheia shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Antheia's last funding round?
Antheia's most recent funding round was Series C Extension on January 27, 2026.
Who are the main investors in Antheia?
Key investors in Antheia include America's Frontier Fund, AFF, Athos KG, EDBI, Viking Global Investors.
Will Antheia IPO soon?
No public IPO plans have been announced for Antheia.
How can I track Antheia secondary market activity?
Caplight tracks bids, offers, and trades in Antheia's shares on secondary markets.